Stocks
Pfizer Financial Statements (PFE) |
||||||||||
| Pfizersmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 27.02.2020 | 25.02.2021 | 24.02.2022 | 23.02.2023 | 22.02.2024 | 08.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 51 750 | 41 908 | 81 288 | 100 330 | 58 496 | 57 239 | |||
| Operating Income, bln rub | 15 137 | 10 630 | 24 833 | 40 030 | 4 235 | 3 905 | ||||
| EBITDA, bln rub | ? | 19 747 | 14 066 | 28 533 | 43 639 | 10 525 | 10 922 | |||
| Net profit, bln rub | ? | 16 273 | 7 020 | 21 979 | 31 372 | 2 119 | 479.0 | |||
| OCF, bln rub | ? | 12 588 | 14 403 | 32 580 | 29 267 | 8 700 | 9 787 | |||
| CAPEX, bln rub | ? | 2 594 | 2 791 | 2 711 | 3 236 | 3 907 | 2 558 | |||
| FCF, bln rub | ? | 9 994 | 11 612 | 29 869 | 26 031 | 4 793 | 7 229 | |||
| Dividend payout, bln rub | 8 043 | 8 440 | 8 729 | 8 983 | 9 247 | 7 001 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 49.4% | 120.2% | 39.7% | 28.6% | 436.4% | 1 462% | ||||
| OPEX, bln rub | 27 610 | 24 456 | 30 232 | 28 714 | 25 048 | 26 379 | ||||
| Cost of production, bln rub | 10 219 | 8 692 | 30 821 | 34 344 | 29 213 | 26 955 | ||||
| R&D, bln rub | 8 650 | 9 405 | 13 829 | 11 428 | 10 578 | 10 428 | ||||
| Interest expenses, bln rub | 1 574 | 1 449 | 1 291 | 1 238 | 2 369 | 2 963 | ||||
| Assets, bln rub | 167 488 | 154 229 | 181 477 | 197 206 | 226 501 | 221 095 | ||||
| Net Assets, bln rub | ? | 63 143 | 63 238 | 77 201 | 95 661 | 89 014 | 92 282 | |||
| Debt, bln rub | 52 145 | 38 274 | 36 998 | 34 870 | 75 041 | 69 539 | ||||
| Cash, bln rub | 9 830 | 12 221 | 31 069 | 22 732 | 12 690 | 11 928 | ||||
| Net debt, bln rub | 42 315 | 26 053 | 5 929 | 12 138 | 62 351 | 57 611 | ||||
| Ordinary share price, rub | 37.1 | 36.8 | 59.1 | 51.2 | 28.8 | 30.5 | ||||
| Number of ordinary shares, mln | 5 569 | 5 555 | 5 601 | 5 608 | 5 643 | 5 657 | ||||
| Market cap, bln rub | 206 833 | 204 480 | 330 739 | 287 354 | 162 462 | 172 652 | ||||
| EV, bln rub | ? | 249 148 | 230 533 | 336 668 | 299 492 | 224 813 | 230 263 | |||
| Book value, bln rub | -30 879 | -14 811 | 2 847 | 916 | -43 669 | -39 843 | ||||
| EPS, rub | ? | 2.92 | 1.26 | 3.92 | 5.59 | 0.38 | 0.08 | |||
| FCF/share, rub | 1.79 | 2.09 | 5.33 | 4.64 | 0.85 | 1.28 | ||||
| BV/share, rub | -5.54 | -2.67 | 0.51 | 0.16 | -7.74 | -7.04 | ||||
| EBITDA margin, % | ? | 38.2% | 33.6% | 35.1% | 43.5% | 18.0% | 19.1% | |||
| Net margin, % | ? | 31.4% | 16.8% | 27.0% | 31.3% | 3.62% | 0.84% | |||
| FCF yield, % | ? | 4.83% | 5.68% | 9.03% | 9.06% | 2.95% | 4.19% | |||
| ROE, % | ? | 25.8% | 11.1% | 28.5% | 32.8% | 2.38% | 0.52% | |||
| ROA, % | ? | 9.72% | 4.55% | 12.1% | 15.9% | 0.94% | 0.22% | |||
| P/E | ? | 12.7 | 29.1 | 15.0 | 9.16 | 76.7 | 360.4 | |||
| P/FCF | 20.7 | 17.6 | 11.1 | 11.0 | 33.9 | 23.9 | ||||
| P/S | ? | 4.00 | 4.88 | 4.07 | 2.86 | 2.78 | 3.02 | |||
| P/BV | ? | -6.70 | -13.8 | 116.2 | 313.7 | -3.72 | -4.33 | |||
| EV/EBITDA | ? | 12.6 | 16.4 | 11.8 | 6.86 | 21.4 | 21.1 | |||
| Debt/EBITDA | 2.14 | 1.85 | 0.21 | 0.28 | 5.92 | 5.28 | ||||
| R&D/CAPEX, % | 333.5% | 337.0% | 510.1% | 353.2% | 270.7% | 407.7% | ||||
| CAPEX/Revenue, % | 5.01% | 6.66% | 3.34% | 3.23% | 6.68% | 4.47% | ||||
| Pfizer shareholders | ||||||||||
